Acute Kidney Injury in Patients With Cancer
Acute kidney injury (AKI) is a common complication in cancer patients and occurs in up to 30% of patients during their disease course. Multiple myeloma, leukemia/lymphoma, renal cell carcinoma, and hematopoietic stem cell transplantation are commonly associated with the development of AKI.07/19/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 19, 2018 Category: Urology & Nephrology Source Type: news

Former Major League Baseball (MLB) All-Stars Dave Winfield And Steve Garvey Team Up With Amgen To Launch Myeloma MVP ™ And Encourage Patients To Create Their Most Valuable Plan For Managing Multiple Myeloma
Discussion With Doctor to Create Individualized Treatment Plan Don Baylor Jr., Son of Former MLB Most Valuable Player Don Baylor, Honors Late Father's Legacy by Raising Multiple Myeloma Awareness Through Campaign Amgen to Recognize Local Multiple Myeloma Communities at Select MLB Games in 2018 THOUSAND OAKS, Calif., July 18, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the launch of Myeloma MVPTM, a national campaign to help those affected by multiple myeloma create their Most Valuable Plan, an individualized approach for managing their disease. Multiple myeloma is an incurable blood ... (Source: Amgen News Release)
Source: Amgen News Release - July 18, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

A 62-Year-Old Man Who Demands Testing: USMLE Question A 62-Year-Old Man Who Demands Testing: USMLE Question
A 62-year-old man who has no acute complaints demands testing for multiple myeloma, due to his father's death. What do his test results show?Osmosis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 13, 2018 Category: Consumer Health News Tags: Med Students Interactive Quiz Source Type: news

Looking at the urine and blood may be best in diagnosing myeloma
(Medical College of Georgia at Augusta University) When it comes to diagnosing a condition in which the plasma cells that normally make antibodies to protect us instead become cancerous, it may be better to look at the urine as well as the serum of our blood for answers, pathologists say. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 13, 2018 Category: Cancer & Oncology Source Type: news

Quiz: Understand the Role of Adipose Tissue in Multiple Myeloma
Our latest quiz highlights the role of bone marrow adiposity in patients with multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - July 10, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Source Type: news

Ixazomib-Based Regimen Is Promising in Newly Diagnosed Multiple Myeloma
Investigators concluded ixazomib “may offer a more convenient, active, and well-tolerated alternative to a parenterally administered PI in this setting.” (Source: CancerNetwork)
Source: CancerNetwork - July 9, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Multiple Myeloma Incidence Increasing Worldwide, Especially in the US
From 1990 to 2016, incident cases of multiple myeloma increased by 126% globally, while deaths increased 94%. The US had the most incident cases and deaths. (Source: CancerNetwork)
Source: CancerNetwork - July 9, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Gene Mutations Dictate Treatment in NCI Clinical Trial
More than 40 patients with mesothelioma have been screened for NCI-MATCH, the novel clinical trial pairing tumor-related gene abnormalities with a drug targeting the corresponding mutation, regardless of cancer type. The multicenter program is the largest precision medicine clinical trial ever conducted, with more than 5,500 patients already participating nationwide. The National Cancer Institute (NCI) sponsors the phase II trial called Molecular Analysis for Therapy Choice (MATCH), which opened in 2015. The study was designed for patients with various solid tumors, myeloma and lymphoma that have progressed after standard-...
Source: Asbestos and Mesothelioma News - July 5, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

FDA-NCI Team Warns Against Single-Arm Pembrolizumab Trials in Multiple Myeloma
An analysis by FDA and NCI investigators recommended further study of the utility of immunotherapy in patients unable to mount adequate immune responses. (Source: CancerNetwork)
Source: CancerNetwork - July 3, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Medical News Today: What types of blood disorders are there?
When the cells in the blood do not function as they should, it is possible a person has a blood disorder. Examples include leukemia, lymphoma, and myeloma. Common blood disorder symptoms include unexplained exhaustion and weight loss. Learn more about the types of blood disorder and the signs to look out for here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 26, 2018 Category: Consumer Health News Tags: Blood / Hematology Source Type: news

Can We Afford the Cost of Myeloma Therapy? Can We Afford the Cost of Myeloma Therapy?
Two experts square off on the issue of drug cost for multiple myeloma -- is care really not affordable, or are most patients able to access treatment?Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 25, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Quiz: Multiple Myeloma Patients With Minimal Residual Disease
Our latest quiz highlights the role of testing for minimal residual disease in the management of multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - June 19, 2018 Category: Cancer & Oncology Source Type: news

Molecular Partners says 5 of 8 patients responded in multiple myeloma trial
ZURICH (Reuters) - Molecular Partners said on Friday that five of eight patients with advanced multiple myeloma in a Phase II study showed an objective response to a combination therapy that includes an investigational drug from the Swiss company. (Source: Reuters: Health)
Source: Reuters: Health - June 15, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Transplant in Myeloma Ups Survival, but Is Underutilized Transplant in Myeloma Ups Survival, but Is Underutilized
Stem cell transplant improves survival in patients with multiple myeloma, but why is it still underutilized?Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 14, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Medical News Today: What is the first sign of multiple myeloma?
Spotting the early signs of multiple myeloma means it is easier to treat the disease. However, this type of cancer has no cure and can lead to other conditions developing. Treatment options depend on the individual case. Learn more about the signs of multiple myeloma, and when to see a doctor, here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 12, 2018 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS ® (carfilzomib) Label
KYPROLIS, Lenalidomide and Dexamethasone Extended Median Overall Survival in Relapsed or Refractory Multiple Myeloma Patients to 48 Months KYPROLIS is the First and Only Treatment to Demonstrate Overall Survival Benefits in Two Phase 3 Studies in Relapsed or Refractory Multiple Myeloma THOUSAND OAKS, Calif., June 11, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to add the positive overall survival (OS) data from the Phase 3 ASPIRE trial to the U.S. Prescribing Information for KYPROLIS® (car...
Source: Amgen News Release - June 11, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

License Not Renewed for UAMS' Myeloma Institute Director
The state medical bBoard will not renew the educational license of Dr. Gareth Morgan, director of the UAMS Myeloma Institute, until he completes a course for distressed physicians. (Source: Arkansas Business - Health Care)
Source: Arkansas Business - Health Care - June 8, 2018 Category: American Health Source Type: news

Bluebird Myeloma Treatment Delays Cancer Progression Bluebird Myeloma Treatment Delays Cancer Progression
Patients with advanced multiple myeloma treated with bluebird bio's experimental immunotherapy lived for a median of nearly a year before their cancer worsened, according to data from a small phase I study presented on Friday.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 5, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Daratumumab/Carfilzomib Combo Effective in Lenalidomide-Refractory MM
Leah LawrenceJun 4, 2018In MMY1001, median PFS was 14.1 months and median OS was 21.1 months in patients with lenalidomide-refractory myeloma treated with daratumumab/carfilzomib. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Pomalidomide Combo PVd Ups PFS in Lenalidomide-Exposed Myeloma
Leah LawrenceJun 3, 2018OPTIMISMM is the only phase III trial to show a significant PFS benefit in R/R MM patients with prior exposure to lenalidomide. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Once-Weekly Bests Twice-Weekly Carfilzomib in R/R Multiple Myeloma
Leah LawrenceJun 2, 2018A once-weekly regimen of carfilzomib plus dexamethasone improved response and delayed progression better than a twice-weekly regimen in R/R MM. (Source: CancerNetwork)
Source: CancerNetwork - June 2, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Genomics Revolution Taking Off in Multiple Myeloma
John SchieszerJun 2, 2018Risk stratification is leading to increasing numbers of new molecular targets in multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - June 2, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Cellular Therapies for Multiple Myeloma: A Paradigm Shift
John SchieszerJun 1, 2018Therapy with CAR T cells may benefit patients with highly refractory multiple myeloma, said U Penn ’s Adam Cohen at ASCO 2018. (Source: CancerNetwork)
Source: CancerNetwork - June 1, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Bluebird Bio's " Impressive " Killer T-Cells Battle Myeloma, But Are Not A Cure Yet
New data show that at a high dose, the CAR-T therapy developed by Bluebird and Celgene shrank tumor in 95 percent of patients and made cancer undetectable in 50 percent. The cancer still returned for most patients. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - June 1, 2018 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NASDAQ:CELG NASDAQ:BLUE Source Type: news

Bluebird myeloma treatment delays cancer progression: trial
CHICAGO (Reuters) - Patients with advanced multiple myeloma treated with bluebird bio's experimental immunotherapy lived for a median of nearly a year before their cancer worsened, according to data from a small study presented on Friday. (Source: Reuters: Health)
Source: Reuters: Health - June 1, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Phase 3 A.R.R.O.W. Interim Analysis Shows Once-Weekly 70 mg/m2 KYPROLIS ® (carfilzomib) Regimen Significantly Extended Progression-Free Survival Versus A Twice-Weekly 27 mg/m2 Regimen In Patients With Relapsed And Refractory Multiple Myeloma
Less Frequent Once-Weekly KYPROLIS Regimen Also Significantly Increased Overall Response Rates With a Comparable Safety Profile Versus a Twice-Weekly Regimen Prespecified Interim Analysis Presented Today During Oral Session at ASCO 2018 and Simultaneously Published in The Lancet Oncology THOUSAND OAKS, Calif., June 1, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the Phase 3 A.R.R.O.W. trial of a once-weekly KYPROLIS® (carfilzomib) dosing regimen in patients with relapsed and refractory multiple myeloma. In the trial, KYPROLIS administered once-weekly at 70 mg/m2 with dexamethasone (once-...
Source: Amgen News Release - June 1, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And MD Anderson Announce Collaboration To Accelerate Early Stage Treatments For Leukemia, Myelodysplastic Syndromes, Multiple Myeloma, Small-Cell Lung And Other Small-Cell Cancers
Efforts to Focus on Pre-Clinical and Clinical Research for up to 16 Early-Stage Programs Across Various Types of Cancer Multi-Year Agreements Build on Long-Term Partnership in Immuno-Oncology, Including BiTE® Therapies and now CAR T Programs THOUSAND OAKS, Calif. and HOUSTON, May 31, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and The University of Texas MD Anderson Cancer Center today announced two multi-year collaboration agreements aimed at accelerating development of a variety of Amgen's early-stage oncology therapies for patients with leukemia, myelodysplastic syndromes, multiple myeloma, small-cell lung ...
Source: Amgen News Release - May 31, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

MD Anderson and Amgen to accelerate early-stage treatments for several cancer types
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Amgen today announced two multi-year collaboration agreements aimed at accelerating development of a variety of Amgen's early-stage oncology therapies for patients with leukemia, myelodysplastic syndromes, multiple myeloma, small-cell lung cancer, and other non-lung cancers with small-cell histologies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 31, 2018 Category: Cancer & Oncology Source Type: news

Janssen Announces Initiation of Phase 1b/2 Clinical Development Program Evaluating JNJ-68284528 CAR-T Cells for the Treatment of Multiple Myeloma
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 30, 2018 Category: Pharmaceuticals Source Type: news

Legend Announces FDA Clearance of IND Application on CAR-T Immuno-cell Therapy for the Treatment of Multiple Myeloma
LCAR-B38M CAR-T therapy (JNJ-68284528) to be developed as part of strategic partnership between Legend and Janssen PISCATAWAY, N.J., May 30, 2018 -- (Healthcare Sales & Marketing Network) -- Legend Biotech, a subsidiary of GenScript Biotech Corporation... Biopharmaceuticals, Oncology, FDA Legend Biotech, GenScript Biotech, Janssen, CAR-T therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 30, 2018 Category: Pharmaceuticals Source Type: news

Discovery of Genes Linked to Myeloma Onset May Drive Personalized Tx
A UK team found multiple targets of non-coding mutations, highlighting the importance of broadening the search for cancer drivers into the regulatory genome. (Source: CancerNetwork)
Source: CancerNetwork - May 9, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

Morning Break: New Myeloma Tx; New EpiPen Shortage? Ticked Off by CDC
(MedPage Today) -- Health news and commentary from around the Web gathered by the MedPage Today staff (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - May 9, 2018 Category: Psychiatry Source Type: news

Daratumumab Now First-Line in Myeloma in US Daratumumab Now First-Line in Myeloma in US
Daratumumab becomes the first antibody approved for first-line use in the treatment of newly diagnosed multiple myeloma, in combination with three other agents.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 9, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Liquid Biopsies Instead of Bone Marrow Biopsy in Myeloma Liquid Biopsies Instead of Bone Marrow Biopsy in Myeloma
Measuring circulating tumor cells in blood samples may one day replace the painful bone marrow biopsies that are currently used to monitor disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 9, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Multiple Myeloma With Severe Abdominal Pain and Diarrhea Multiple Myeloma With Severe Abdominal Pain and Diarrhea
In this unusual case, diarrhea and abdominal pain were the initial presenting symptoms of multiple myeloma with a plasmacytoma.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 9, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Maintenance Bortezomib: No Improved Depth of Reponse in “Plateaued” MM
Investigators concluded further investigations are warranted in elderly patients with either stable or responsive disease after bortezomib induction therapy. (Source: CancerNetwork)
Source: CancerNetwork - May 8, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Immuno Oncology Multiple Myeloma News Source Type: news

Maintenance Bortezomib: No Improved Depth of Response in “Plateaued” MM
Investigators concluded further investigations are warranted in elderly patients with either stable or responsive disease after bortezomib induction therapy. (Source: CancerNetwork)
Source: CancerNetwork - May 8, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Immuno Oncology Multiple Myeloma News Source Type: news

Quiz: Management of Transplant-Ineligible Multiple Myeloma
Bryant FurlowMay 8, 2018Challenge yourself with our latest quiz, covering management considerations in the treatment of patients with transplant-ineligible myeloma. (Source: CancerNetwork)
Source: CancerNetwork - May 8, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Janssen Announces DARZALEX ® (daratumumab) U.S. FDA Approval for Newly Diagnosed Patients with Multiple Myeloma who are Transplant Ineligible
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 8, 2018 Category: Pharmaceuticals Source Type: news

Janssen Announces Darzalex (daratumumab) U.S. FDA Approval for Newly Diagnosed Patients with Multiple Myeloma who are Transplant Ineligible
HORSHAM, PA, May 7, 2018 – The Janssen Pharmaceutical Companies of Johnson& Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab) in combination with Velcade (bortezomib)*, a proteasome... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 7, 2018 Category: Drugs & Pharmacology Source Type: news

Newton ’s Karyopharm to seek FDA approval for cancer drug after trial win
Newton-based Karyopharm Therapeutics said Monday that it plans to seek FDA approval for its lead cancer drug later this year following the success of a mid-stage trial involving patients who had not responded to several previous treatments. Karyopharm (Nasdaq: KPTI) said that 25 percent of multiple myeloma patients in the trial had responded to treatment with the drug, called selinexor. As a result, the company announced plans to seek accelerated approval from the FDA in the second half of 2018. Shares… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 30, 2018 Category: Pharmaceuticals Authors: Max Stendahl Source Type: news

Newton ’s Karyopharm to seek FDA approval for cancer drug after trial win
Newton-based Karyopharm Therapeutics said Monday that it plans to seek FDA approval for its lead cancer drug later this year following the success of a mid-stage trial involving patients who had not responded to several previous treatments. Karyopharm (Nasdaq: KPTI) said that 25 percent of multiple myeloma patients in the trial had responded to treatment with the drug, called selinexor. As a result, the company announced plans to seek accelerated approval from the FDA in the second half of 2018. Shares… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 30, 2018 Category: Biotechnology Authors: Max Stendahl Source Type: news

Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To KYPROLIS ® (carfilzomib) Label
KYPROLIS is the First and Only Relapsed or Refractory Multiple Myeloma Treatment to Demonstrate Overall Survival in two Phase 3 Studies THOUSAND OAKS, Calif., April 30, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a label variation for KYPROLIS® (carfilzomib) to include the final overall survival (OS) data from the Phase 3 ASPIRE trial. The ASPIRE trial demonstrated that the addition of KYPROLIS to lenalidomide and dexamethasone (KRd) reduced the risk of deat...
Source: Amgen News Release - April 30, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Higher Myeloma Precursor Risk in WTC Responders (CME/CE)
(MedPage Today) -- More data on 9/11 firefighter cancer risk (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - April 27, 2018 Category: American Health Source Type: news

Study: MS drug may diminish side effects in myeloma treatment
A drug commonly used to treat multiple sclerosis could reduce the effects of a chemotherapy of myeloma patients, according to a study of mice. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 27, 2018 Category: Consumer Health News Source Type: news

In multiple myeloma, different types of blood biopsies match up well with bone marrow tests
(Dana-Farber Cancer Institute) Scientists from the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard have shown that two ways to measure multiple myeloma DNA in blood samples provide highly detailed sets of genetic information that agree well not just with each other but with results from bone marrow tests. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 27, 2018 Category: International Medicine & Public Health Source Type: news

Multiple sclerosis drug could reduce painful side effects of common cancer treatment
(Rockefeller University Press) Researchers from the Saint Louis University School of Medicine have discovered why many multiple myeloma patients experience severe pain when treated with the anticancer drug bortezomib. The study, which will be published April 27 in the Journal of Experimental Medicine, suggests that a drug already approved to treat multiple sclerosis could mitigate this effect, allowing myeloma patients to successfully complete their treatment and relieving the pain of myeloma survivors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 27, 2018 Category: Cancer & Oncology Source Type: news

Multiple Myeloma Risk May Be Up for WTC - Exposed Firefighters
And, cancer burden projected to be greater than expected for world trade center - exposed firefighters (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 26, 2018 Category: Cancer & Oncology Tags: Family Medicine, Internal Medicine, Oncology, Pathology, Journal, Source Type: news

Blood Cancer Precursor Found in 9/11 Firefighters
April 26, 2018—(BRONX, NY)— A study in today’s issue ofJAMA Oncology reports that New York City firefighters exposed to the 9/11 World Trade Center disaster site face an increased risk for developing myeloma precursor disease (MGUS), which can lead to the blood cancer multiple myeloma. The study was conducted by researchers atAlbert Einstein College of Medicine,Montefiore Health System, theFire Department of the City of New York (FDNY) andMemorial Sloan Kettering Cancer Center. (Source: Einstein News)
Source: Einstein News - April 26, 2018 Category: Universities & Medical Training Source Type: news